Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464543 | 0.85 | SLC5A2 (0.42) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12334424 | 0.80 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL2464271 | 0.80 | SLC5A2 (0.42) | SLC5A2SLC5A1 | |
| SCHEMBL2461883 | 0.80 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL15368893 | 0.80 | SLC5A2 (0.38) | SLC5A2SLC5A1 | |
| SCHEMBL12601656 | 0.76 | TSHR (0.56) | CYP3A4 | |
| SCHEMBL12308543 | 0.75 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL12308544 | 0.74 | SLC5A2 (0.57) | SLC5A2SLC5A1 | |
| SCHEMBL148077 | 0.74 | SLC5A2 (0.57) | SLC5A2SLC5A1 | |
| SCHEMBL2462728 | 0.74 | SLC5A2 (0.57) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | SLC5A2 1/4885CYP3A4 2655/4885SSTR1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.